Int. J. Pharm. Sci. Rev. Res., ISSN: 0976 – 044X, 86(4) – April 2026; Article No. 06, Pages: 41-52 **DOI:** 10.47583/ijpsrr.2026.v86i04.006

Review Article

Understanding ICH Q14: Principles and Approaches for Analytical Procedure Development

M. Satwika[1], Dr. Khagga Bhavya Sri[*2]

[*1]Professor and Head, Department of Pharmaceutical Analysis, RBVRR Women's college of Pharmacy, Barkatpura, Hyderabad -500027, Telangana, India.

[2]Research Student, Department of Pharmaceutical Analysis, RBVRR Women's college of Pharmacy, Barkatpura, Hyderabad -500027, Telangana, India.

***Corresponding author's E-mail:** bhavya.khagga@gmail.com

Received: 09-02-2026; **Revised:** 28-03-2026; **Accepted:** 05-04-2026; **Published online:** 20-04-2026.

ABSTRACT

The ICH Q14 guideline provides a standardized framework for developing, maintaining, and managing analytical procedures for pharmaceutical substances and products. It aims to align scientific, risk-based, and lifecycle techniques in method development to ensure that analytical procedures are appropriate for their intended use, robust when in use, and flexible in their post-approval management. ICH Q14 is a significant breakthrough in regulatory research concerning pharmaceutical testing methods. This guideline aims to improve method robustness, permit post-approval adjustments, and encourage advanced analytical design and control procedures by emphasizing a scientific, risk-informed, life-cycle-based approach. This helps ensure that analytical methods consistently generate high-quality data in accordance with important quality requirements and expedites regulatory interactions when revisions are needed. The ICH Q14 Guideline offers a scientific and risk-based framework for developing analytical methods used in the assessment of pharmaceutical substances and products. It incorporates concepts of Quality by Design (QbD) and emphasizes Analytical Procedure Development (APD) principles to increase method robustness and reliability. The guideline describes methods for method selection, control, and lifecycle management, which encourages a more flexible regulatory approach. By encouraging methodical method creation, risk assessment, and knowledge management, Q14 fosters innovation and continuous improvement of analytical processes. This ensures consistent product quality and encourages regulatory efficacy in global markets. ICH Q14 and ICH Q2(R2), which deal with validation characteristics and performance verification, are closely related. When taken as a whole, these recommendations offer a thorough framework that addresses both validation and analytical development. Beyond initial validation, the lifetime idea highlighted in Q14 include continuous monitoring, change management, and analytical procedure improvement. All things considered, ICH Q14 improves regulatory harmonization by defining precise standards for analytical advancement throughout ICH regions. The recommendation increases trust in analytical data used to guarantee the efficacy, safety, and quality of pharmaceutical goods by encouraging lifecycle management, scientific rigor, and transparency.

Keywords: Analytical target profile (ATP), lifecycle management, quality, efficiency, analytical procedure control strategy, post-approval change management.

GRAPHICAL ABSTRACT

HISTORY

In order to encourage major regulatory bodies and industry stakeholders to harmonize pharmaceutical regulatory standards globally, the International Council for Harmonization (ICH) was founded in 1990.ICH Q14 was created to complement and work in parallel with the revision of ICH Q2 (Q2(R2)), which focuses on analytical validation.[1]

Q14 describes how to scientifically design, comprehend, and manage analytical processes from development to normal use, while Q2 specifies how to demonstrate technique performance. ICH Q14 reached Step 4 in 2022, signifying the approval of regulations by ICH members.[2]

Including the definition of the Analytical Target Profile, the identification of crucial method parameters, the creation of method operable design regions (MODR), and lifecycle management techniques, the finalized guideline offered an organized, science-based framework for the development of analytical procedures. Crucially, Q14 also coincided with the concurrent revision of ICH Q2(R2), guaranteeing coherence between expectations for method development and validation. Adoption of ICH Q14 signifies a dramatic change from a paradigm that is just validation-focused to one that is lifecycle-oriented. [3]

When backed by scientific understanding and risk management concepts, it promotes improved comprehension of analytical techniques, more regulatory flexibility, and more effective post-approval modifications.[4]



Figure 1: This image explains about analytical target profile

SCOPE

Coverage of the development of analytical procedures: ICH Q14 is applicable to the creation of analytical methods for testing medication ingredients and drug products. Its scope includes both qualitative and quantitative analytical techniques designed to assess quality parameters such as identification, strength, purity, and potency. Chromatographic, spectroscopic, biological, and multivariate analytical procedures are among the conventional and sophisticated analytical techniques that the guideline recommends.[5]

Q14 addresses the full development process, in contrast to previous guidelines that mostly focused on validation features. To guarantee consistent analytical performance, this entails defining the Analytical Target Profile (ATP), determining critical method parameters (CMPs), comprehending method performance characteristics, and creating control measures.[6]

Usefulness Throughout the Product Lifecycle: From initial development to regulatory submission and post-approval monitoring, the guideline covers the full lifespan of analytical processes. Later in the product's lifecycle, more adaptable regulatory methods are made possible by its encouragement of methodical knowledge generation during development.[7]

Q14 encourages ongoing development and, when backed by scientific knowledge and risk assessment, makes post-approval modifications easier. Combining Enhanced Techniques with Quality Risk Management. Integrating Quality Risk Management (QRM) principles is a crucial aspect of its scope. Design of Experiments (DoE) and the creation of a Method Operable Design Region (MODR) are two examples of improved, systematic methodologies that can be used in analytical method development under Q14.[8]

Regulatory Submission Requirements: The information that should be included in regulatory filings about the development of analytical procedures is outlined in ICH

Q14. Development studies, robustness studies, risk assessments, and method parameter justification are a few examples of this. Instead of depending only on end-point validation data, it supports structured documentation that shows scientific comprehension.[9]

Associated with Validation: Although Q14's scope and validity are closely related, they are still separate. ICH Q2(R2) describes performance verification and validation features, while Q14 concentrates on the development of analytical techniques to achieve predetermined goals. When combined, these rules offer a thorough framework that addresses both development and validation tasks.[10]

Types of Covered Products: The guideline covers specific post-approval modifications as well as analytical processes for new medicinal substances and products. For pharmaceutical items submitted within ICH regions, including small compounds and biologics, it is pertinent. Clinical bioanalytical techniques utilized in pharmacokinetic investigations, however, are covered by other guideline publications and are not expressly addressed in this article. The guideline covers specific post-approval modifications as well as analytical processes for new medicinal substances and products. [11]

For pharmaceutical items submitted within ICH regions, including small compounds and biologics, it is pertinent. Clinical bioanalytical techniques utilized in pharmacokinetic investigations, however, are covered by other guideline publications and are not expressly addressed in this article.[12]



Figure 2: This image explains about analytical procedure lifecycle

INTRODUCTION

Q14 encourages a more flexible, risk-based strategy that encourages creativity, fortifies method resilience, and facilitates regulatory adaptation, in contrast to traditional method development, which typically focuses on fixed techniques. According to the principles of Quality by Design (QbD), it offers a systematic, empirically supported approach that aims to improve technique understanding and performance across the product lifecycle.[13]

The analytical life cycle, which is often regulated by ICH Q14 and USP <1220, is a framework that encompasses the entire lifecycle of an analytical technique, from inception to retirement. Its three main stages are Procedure Design (creation, understanding, and risk assessment), Procedure Performance Qualification (PPQ, which includes validation and verification), and Continuous Procedure Performance Verification (CPPV, the method's ongoing regular use and monitoring).[14]

Step 1: Design and Development of Analytical Procedures: The Analytical Target Profile (ATP) is defined at the start of the lifetime. Accuracy, precision, range, and specificity are just a few of the performance standards that the ATP outlines in detail. This predetermined goal guarantees that development efforts are in line with the test's intended function (e.g., assay, impurity profiling, dissolution, identification).[15]

Critical quality attributes (CQAs) of the product or medicinal ingredient. Analytical performance is influenced by critical method parameters (CMPs).Variability sources and possible dangers. Tools for risk assessment are frequently used to rank experimental investigations. To comprehend interactions between technique parameters, a methodical approach like Design of Experiments (DoE) may be employed.[16]

Step 2: Qualification of Analytical Procedure Performance (Validation): After the method design is complete, it is validated to ensure that it satisfies predetermined ATP requirements. The validation principles outlined in ICH Q2 (R2) are consistent with this step. Typically, validation assesses: Accurate, Precision (both intermediate precision and repeatability), Particularty, Ranges and linearity, Limits for detection and quantitation (if relevant), Strongness.[17]

The Analytical Procedure Lifecycle's Stages

1. Development of Analytical Procedures: The primary objectives of this initial phase are the development and creation of the analytical procedure. It comprises selecting appropriate strategies, understanding key aspects of the technique, and utilizing risk assessment tools to identify variables that could impact method performance. The data gathered here supports the method's resilience and establishes the framework for future validation and control strategies.[18]

2. Analytical Procedure Validation: This stage ensures the system's long-term reliability and promotes additional development. At this point, the generated technique is assessed to make sure it fits predetermined requirements and operates dependably. This stage guarantees that the process is appropriate for its intended use and can reliably produce precise results.[19]

3. Continued Procedure Performance Verification (Lifecycle Managemen) Following validation and implementation, continuous monitoring is required to make sure the method keeps working as intended over time. This phase guarantees long-term technique reliability and encourages further improvement.

AQbD, or Analytical Quality by Design: Q14 introduces the concept of Analytical Quality by Design, which extends traditional QbD concepts to analytical procedures. It involves developing an Analytical Target Profile (ATP), identifying Critical Method Parameters (CMPs), and understanding the relationship between CMPs and method performance.[20]

Profile of Analytical Targets (ATP): The ATP outlines the objective of the analytical procedure, including the required performance level. It acts as a guide for method development and helps ensure that the final process meets the required quality standards.

ATP, or defined performance criteria: The Analytical Target Profile (ATP) defines the performance standards that are intended for the procedure. The method must be created and maintained in accordance with specific standards to guarantee fitness for purpose. What has to be measured (e.g., active ingredient assay, dissolving rate, impurity quantification).[22]

The necessary performance level, measured in terms of sensitivity, range, specificity, accuracy, and precision. To put it simply, the ATP provides a solution to the question, "What level of analytical performance is necessary to make reliable quality decisions. The ATP guarantees that the method design, validation, and lifecycle management are all in line with the test's intended purpose by outlining expectations at the outset of development.[23]

MODR, or Method Operable Design Region: A set of technique circumstances where the procedure consistently yields satisfactory outcomes is referred to as MODR. It allows for flexible procedure alterations without the need for regulatory reapproval or revalidation.[21]

Guidelines for ICH Q14 Quality Standards

Figure 3: This image explains about quality standards

Adaptability Within Defined Limits (MODR): Methods can be changed without compromising quality within a designated Method Operable Design Region (MODR). This flexibility encourages continuous improvement while maintaining regulatory compliance.

Documentation and Data Integrity: Accurate, thorough, and verifiable documentation is essential. Q14 conforms to broader data integrity standards by ensuring that all development, validation, and lifecycle procedures are fully documented and auditable.[24]

Product QbD versus Analytical QbD

Table 1: This table explains about product and analytical Qbd

Aspect	Analytical QbD (AQbD)	Product QbD
Focus Area	Development of analytical procedures (e.g., testing methods for drug substances/products)	**Development and manufacturing of pharmaceutical products (e.g., tablets, injections)**

Table 2: This table briefly explains product and analytical Qbd

Objective	Ensure reliable, robust, and consistent method performance	Ensure product meets predefined quality attributes throughout its lifecycle
Key Output	Analytical procedure that meets the **Analytical Target Profile (ATP)**	Drug product that meets the **Quality Target Product Profile (QTPP)**
Risk Assessment	Identifies **Critical Method Parameters (CMPs)** affecting method performance	Identifies **Critical Quality Attributes (CQAs)** and **Critical Process Parameters (CPPs)** affecting product quality
Design Space	Establishes a **Method Operable Design Region (MODR)** where method performs reliably	Establishes a **Design Space** for manufacturing processes where product quality is maintained
Validation/ Control	Method validation confirms method performance; ongoing verification ensures consistency	Process validation confirms product quality; control strategies ensure consistent production
Lifecycle Management	Focused on performance monitoring and continuous improvement	Involves product quality monitoring, change management, and continual improvement of processes
Regulatory Flexibility	Allows method changes within MODR without regulatory re-approval	Allows manufacturing changes within design space under certain regulatory frameworks

ICH Q14 can be used for:

Chemical-based drug ingredients and products (e.g., tablets, capsules, and solutions) . biological and biotechnological products (such as monoclonal antibodies, vaccinations, and recombinant proteins). Both recently released products and those that are sold commercially (like lifecycle updates) . [25]

Improved analytical methods are beneficial for both complex biological products and small compounds due to their broad range of applications. Creating a distinct Analytical Target Profile (ATP) is one of the main applications of ICH Q14. Accuracy, precision, specificity, and range are only a few of the performance requirements that an analytical technique must fulfill according to the ATP. Organizations can create experiments and choose method parameters that directly support the method's intended goal by outlining these expectations early in the development process. This methodical approach reinforces the argument for method performance and enhances clarity during regulatory filings.[26]

Additionally, ICH Q14 is used to promote analytical development based on risk and science. It promotes the use of risk assessment instruments to pinpoint crucial methodological factors that might affect analytical performance. ICH Q14 is also used at every stage of the lifecycle of an analytical technique. After initial validation, the guideline encourages continuous improvement and performance monitoring. The analytical method can be assessed and modified utilizing a lifetime approach if manufacturing processes, formulations, or new contaminants are discovered. This guarantees that the process will continue to be appropriate for its intended usage throughout commercial production.[27]

ICH Q14 is utilized to direct the development of systematic analytical methods, enhance scientific comprehension, enhance regulatory communication, and incorporate lifecycle management into pharmaceutical quality systems. Its application improves the long-term sustainability, robustness, and dependability of analytical techniques used to guarantee the efficacy, safety, and quality of products. The main purpose of the ICH Q14 Guideline is to give the pharmaceutical sector an organized and standardized framework for the development of analytical procedures. [28]

The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use published the guideline, which aids producers in creating analytical techniques that are trustworthy, scientifically sound, and appropriate for their intended use. Instead of depending solely on conventional trial-and-error methods, it guarantees that analytical techniques used for assessing drug ingredients and drug products are created methodically.[29]

Covered Analytical Procedures:

This broad spectrum of applications ensures that improved analytical methods are beneficial for both chemical-based drug ingredients and products (e.g., tablets, capsules, and solutions) . [30]

biological and biotechnological products (such as monoclonal antibodies, vaccinations, and recombinant proteins). The primary goal of the guideline is the advancement of analytical methods. Identity verification (substance testing) Assay for a drug substance or product (testing strength or content) . Evaluation of performance (e.g., particle size, solubility, and potency). Titration, spectroscopy, and bioassays are only a few of the technologies used in the scope, which encompasses both qualitative and quantitative techniques.[31]

Tests of Identification:

Identification processes verify the identity of a product component or medicinal ingredient. These tests guarantee that the right material is present and that there isn't any labeling or substitution. Some examples are: Using infrared (IR) spectroscopy to fingerprint structures, Visible and UV spectroscopy, Comparing chromatographic retention times, Confirmation by mass spectrometry, Performance standards for identification techniques usually place a strong emphasis on specificity, guaranteeing that the analyte can be separated from contaminants, excipients, or degradation products[32]

Quantitative Tests (Potency or Content Tests): The level or potency of the active pharmaceutical ingredient (API) in a drug substance or final product is ascertained by assays. These are essential to guaranteeing the right dose strength. Common methods include Liquid chromatography with high performance (HPLC), Titrimetric approaches, Assays for spectrophotometry, For biological products, bioassays. To enable trustworthy content determination, these processes must exhibit the proper accuracy, precision, range, and robustness. Tests for Degradation and Impurity Products: These methods quantify pollutants, impurities, and degradation products that could compromise stability and safety.[33]

They could consist of: Separation by chromatography using UV or MS detection, Indicators of stability, Tests for limiting trace contaminants, Strong specificity and sensitivity are necessary for these techniques, which frequently have specified detection and quantitation limitations.[34]

Tests for Drug Release and Dissolution: Dissolution testing assesses the pace and degree of drug release under particular conditions for solid oral dose forms and some modified-release products. Usually, these examinations include: Dissolution equipment with regulated agitation and pH, Sampling at specified intervals, Quantification by spectroscopic or chromatographic methods

Reproducibility and the capacity to identify significant variations in release behavior are the main performance requirements.[35]

Regulatory and Lifecycle Integration:

The ICH Q14 Guideline's regulatory and lifecycle integration represents a contemporary approach that views analytical techniques as dynamic components of the pharmaceutical quality system rather than as static, once-validated approaches. Q14, which was created by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, synchronizes lifecycle management concepts with regulatory requirements. [36]

Throughout the product's commercial life, this integration guarantees that analytical processes are designed scientifically, suitably validated, openly documented, and consistently kept under control. From a regulatory standpoint, pharmaceutical development is where lifecycle integration starts. In regulatory submissions, the guideline urges applicants to provide a concise Analytical Target Profile (ATP), a well-organized synopsis of development studies, and a rationale for method selection. Regulators are given a thorough understanding of how the technique was created to satisfy predetermined performance objectives, rather than concentrating only on validation results. [37]

More flexible, risk-based regulatory decisions are supported by this increased transparency, which also makes scientific communication between industry and regulatory bodies easier. The idea of better method comprehension is a key component of lifecycle and regulatory integration.[38]



Figure 4: This image explains the flow chart for control of risk and risk management

This information can be used to support regulatory flexibility when applicants produce solid scientific knowledge, such as identifying crucial method parameters and specifying method operable design regions. Certain modifications may be made by the company's internal quality system within predetermined and permitted parameters instead of needing prior regulatory permission. This maintains assurance of method performance and product quality while reducing needless regulatory burden. Through continuous performance monitoring and change management, lifecycle integration is maintained throughout the commercial phase. [39]

Trend analysis, system appropriateness findings, out-of-specification investigations, and other quality indicators are used to examine analytical processes on a regular basis. A risk-based method is used to assess how process, formulation, or scale-up operations can affect analytical performance.[40]

To prove continuous appropriateness, verification or partial revalidation investigations are carried out as needed. Even as products and procedures change, this methodical approach guarantees that regulatory compliance is upheld. [41]

Essentially, Q14's regulatory and lifecycle integration encourages a proactive, scientifically grounded connection between regulatory monitoring and development expertise. The guideline improves worldwide harmonization, increases method robustness, and facilitates effective post-approval management by integrating analytical processes into a comprehensive quality management framework.[42]

In the end, this integrated model supports consistent product quality, regulatory trust, and ongoing development across the course of the pharmaceutical product lifecycle.[43]

Knowledge management lifecycle: This broad spectrum of applications ensures that improved analytical methods are beneficial for both Chemical-based drug ingredients and products (e.g., tablets, capsules, and solutions) . biological and biotechnological products (such as monoclonal antibodies, vaccinations, and recombinant proteins). Structured data generation is the first step in knowledge management throughout the development phase. Researchers gather data from previous studies, literature, platform expertise, and preliminary feasibility tests. Risk assessments are carried out to find factors that might affect analytical performance. [44]

To determine how technique parameters impact outcomes, experimental studies are carried out, possibly incorporating Design of Experiments (DoE) and robustness evaluations. The emphasis is on developing a thorough understanding of method behavior, variability causes, and performance constraints rather than just improving settings. Clear performance expectations, such the Analytical Target Profile (ATP), can be established with the help of this fundamental knowledge. After development studies are finished, the gathered data needs to be methodically recorded and arranged. Development reports, risk assessment records, validation processes, data summaries, and the rationale behind chosen circumstances are all examples of proper documentation.[45]

The traceability of scientific judgments is guaranteed by organized documentation. For instance, if a certain chromatographic condition is chosen, it is important to document the experimental justification and supporting information. Electronic systems or regulated document management platforms are examples of organized knowledge repositories that make it simple to retrieve information for audits, inspections, or regulatory submissions. This broad spectrum of applications ensures that improved analytical methods are beneficial for both sChemical-based drug ingredients and products (e.g., tablets, capsules, and solutions) biological and biotechnological products (such as monoclonal antibodies, vaccinations, and recombinant proteins).[46]

Figure 5: This image explains about knowledge management lifecycle

Risk management- Refers to the systematic process of identifying, investigating, evaluating, and controlling potential risks that could jeopardize the reliability and efficacy of an analytical methodology. It guarantees analytical techniques are: Science-based justification Fit for the function for which they were designed capacity to produce consistent results over a long length of time. Risk identification is the first step in the process, which involves methodically identifying potential sources of failure or variability.[47]

Sample preparation techniques, instrument settings, ambient factors, reagent variability, analyst technique, and data processing methods can all provide risks in analytical procedures. At this point, multidisciplinary teams frequently examine scientific concepts, experimental data, and past knowledge to identify the variables that might have a major impact on technique performance. The objective is to compile a thorough list of potential failure modes without making snap judgments about how serious they might be. Risk analysis, which comes after identification, entails evaluating the probability, seriousness, and detectability of each risk that has been discovered. Fishbone diagrams, risk ranking matrices, and Failure Mode and Effects Analysis (FMEA) are examples of tools that can be used to assess and rank risks.[48]

A little change in the composition of the mobile phase, for instance, may have a moderate likelihood but a significant effect on chromatographic resolution, making it a high-priority factor for additional research. Rather than evaluating every variable equally, risk analysis helps concentrate resources on the most important factors. Following investigation, risk appraisal establishes whether the hazards found are acceptable or need to be mitigated. The Analytical Target Profile (ATP)-aligned predetermined criteria serve as the basis for this conclusion.[49]

A risk needs to be handled if it jeopardizes the method's capacity to fulfill performance standards, such as accuracy, precision, or specificity. Regulatory openness is supported by evaluation, which guarantees that risk decisions are supported by research and documented. The following stage, risk control, entails putting plans in place to lessen or get rid of unacceptable risks. Optimizing method circumstances, tightening system suitability standards, enhancing training protocols, or setting operating ranges for crucial method parameters are a few examples of control approaches.[50]

Design of Experiments (DoE) is a useful tool for defining robust operating regions and improving understanding of parameter interactions in enhanced development methodologies. The goal of risk control is to guarantee that the procedure is dependable even in the event of little deviations from standard laboratory procedures. ICH Q9 (Quality Risk Management) is strongly related to Q14's risk management, which is integrated throughout the analytical lifecycle. There are a number of benefits to an efficient risk management framework. [51]

It increases resilience, decreases unforeseen failures, promotes effective resource usage, and advances scientific understanding of analytical techniques. Laboratories can avoid analytical errors that could impair product quality or postpone regulatory approval by focusing their efforts on high-impact factors. To sum up, risk management in analytical procedure creation is a methodical, science-based process that incorporates risk identification, assessment, control, and ongoing review. It guarantees that analytical techniques are dependable, strong, and able to continuously support wise pharmaceutical quality decisions throughout their lifecycle, guided by the principles in ICH Q9 and reaffirmed in ICH Q14.[52]



Figure 6: This image explains risk management and risk control

Real-Time Release Testing (RTRT):

Enables the assessment and guarantee of a product's quality based on process data and/or analytical results during manufacture, as opposed to waiting for final end-product testing. RTRT is a state-of-the-art technique that expedites batch releases, increases production efficiency, and immediately ensures product quality. A sophisticated quality assurance method called Real-Time Release Testing (RTRT) bases product release decisions not only on end-product testing but also on process data and in-process controls.[53]

RTRT is in line with contemporary quality concepts that prioritize scientific comprehension, risk management, and lifecycle control within the pharmaceutical regulatory framework of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. RTRT uses validated monitoring systems and predetermined acceptance criteria to verify product quality throughout production, as opposed to waiting for laboratory test results after manufacturing is finished. The ideas presented in ICH Q8, which encourages improved process comprehension and design space creation, are strongly related to RTRT. Manufacturers can create trustworthy control plans when they fully comprehend how material characteristics and process parameters impact critical quality attributes (CQAs). [54]

Online, in-line, or at-line analytical equipment that may continually measure parameters like mix homogeneity, moisture level, or content uniformity are examples of these tactics. It is possible to minimize the requirement for comprehensive end-product testing by making sure the process continuously functions inside a proven design area. A key enabling technology for RTRT is Process Analytical Technology (PAT). PAT tools provide real-time measurement and control of critical variables during manufacturing. [55]

For example, spectroscopic methods or sensor-based systems can monitor chemical composition or physical properties without interrupting production. When these tools are properly developed, validated, and integrated into the quality system, they generate reliable data that can support immediate release decisions. The scientific foundation of these methods must demonstrate accuracy, precision, specificity, and robustness comparable to conventional laboratory tests. When implementing RTRT, quality risk management is crucial. Manufacturers are required by ICH Q9 to assess the possible hazards of substituting process-based controls for traditional testing. This entails evaluating model maintenance, failure situations, data reliability, and system applicability. Redundant controls, alarm systems, and regular verification testing are examples of mitigation techniques that are crucial to guaranteeing that product quality is not jeopardized. According to ICH Q10, RTRT also necessitates robust lifecycle management within the pharmaceutical quality system.[56]

Maintaining trust in the real-time system requires ongoing process performance monitoring, analytical tool calibration, and recurring model verification. A structured change management procedure must be used to assess how process modifications affect analytical measurements or prediction models. This guarantees ongoing adherence to regulations and long-term stability. Faster product release, less laboratory work, better process control, and increased manufacturing efficiency are just a few of the practical benefits that RTRT delivers. However, thorough scientific knowledge, solid analytical validation, and open regulatory communication are necessary for successful implementation. RTRT is a step toward proactive quality assurance that guarantees pharmaceutical goods continuously satisfy predetermined requirements of safety, efficacy, and quality without needless delay when correctly planned and maintained.[57]



Figure 7: This image explains Real Time Release Testing

Documentation must contain scientific rationale for the choices of methods. justification for risk-based approaches and control ranges. Evidence of the method's adaptability to shifting conditions. Clarity and adaptability within designated operational ranges (e.g., Method Operable Design Regions, or MODRs). traceability of the decision-making and validation procedures. Multivariate analytical processes (MVAPs) are sophisticated analytical methods that use multiple variables simultaneously to analyze difficult data. They commonly rely on chemometric models and are employed in real-time or virtually real-time testing environments, such as: Process Analysis Technology (PAT) , Real-Time Release Testing (RTRT), Techniques for spectroscopy like Raman, FTIR, and NIR. [58]

Sample Population:

The sample population is the specific subset of the entire population chosen for research. It includes the individuals or objects that are actually observed or measured in a study. A sample population is a selection of objects, people, materials, or observations chosen from a larger population for testing, analysis, or study. Batches of raw materials, completed dosage units, biological specimens, or stability samples selected to reflect the entire product or process might make up the sample population in analytical and pharmaceutical contexts. Making sure that test results are both really representative of the total population and scientifically valid is the primary goal of identifying a suitable sample population. All product forms, strengths, formulations, intermediates, and stability conditions that the method will come across are included in the sample population when developing analytical procedures. This could include various excipient compositions, varied manufacturing sizes (pilot and commercial batches), degradation products generated during stability studies, and possible contaminants. Developers guarantee that experimental investigations capture real-world variability and that the analytical process is robust when used for routine quality control testing by precisely characterizing the sample population.[59]

Forced degradation samples and stability research batches kept in different environmental settings are included in the sample population for stability-indicating techniques. The method's ability to separate the active medicinal ingredient from its degradation products is ensured by the inclusion of deteriorated samples. In a similar vein, spiked samples with known impurities at specification limits may be included in the sample population for impurity testing processes in order to verify sufficient detection and quantification capabilities.[60]

The definition of the sample population may change during lifetime management. New variability may be introduced through formulation changes, manufacturing process alterations, or scale-up initiatives. Any substantial modification that modifies the sample population should prompt an evaluation of whether the analytical process is still appropriate in accordance with Q14 principles. To show ongoing performance, this could entail more verification research or a partial revalidation. In conclusion, the sample population in the Q14 framework is a thorough depiction of every material that the analytical process is meant to examine. Its correct definition guarantees that method creation, validation, and continuous performance verification are based on circumstances that are reasonable and supported by science. Q14 encourages robustness, dependability, and regulatory confidence in pharmaceutical quality control testing by including sample population considerations throughout the analytical method lifetime.[61]



Figure 8: This image explains about sample population

CONCLUSION

The ICH Q14 guideline's conclusion highlights the necessity of a science-and risk-based strategy in the development of analytical procedures throughout the lifetime of pharmaceutical goods. It significantly supports the principle of Quality by Design (QbD) in both manufacturing and analytical processes, and it closely aligns with the guidelines presented in ICH Q8–Q12. To sum up, the ICH Q14 Guideline is a significant step forward for the pharmaceutical industry's scientific and regulatory approach to developing analytical procedures. This guideline, which was created by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, creates a unified framework that incorporates lifecycle thinking, risk management concepts, and scientific knowledge into the development and upkeep of analytical techniques. Q14 guarantees that analytical processes are not only verified at a single point in time but continue to be dependable and appropriate for use throughout the product's commercial life by moving the emphasis from a simply validation-centered approach to a thorough lifecycle strategy. As the basis for method development and performance evaluation, the guideline highlights the significance of precisely establishing the Analytical Target Profile (ATP). Q14 promotes producers to include quality into analytical processes from the beginning through methodical development studies, improved method understanding, and suitable control strategies. This methodical approach enables regulatory flexibility, lowers the risk of method failure, and strengthens the overall resilience of quality control systems.

A Lifecycle View of Analytical Techniques: The guideline highlights that the process of creating an analytical

DOI: 10.47583/ijpsrr.2026.v86i04.006

procedure is ongoing. Instead, it is a continuous, dynamic, and iterative process that continues throughout the duration of the product's existence. As product knowledge and analytical technologies improve, procedures can be created and improved to ensure continued appropriateness.

Report on Analytical Procedure Development: It is recommended that a development report has a well-defined structure. The selected analytical methods and their performance characteristics are supported scientifically in this study.[59] It facilitates regulatory submissions and enhances communication with regulatory bodies, particularly when upgrades or modifications are made along the lifespan.

Regulation Flexibility: Implementing QbD concepts, such as developing an Analytical Target Profile (ATP) and using effective method development methodologies, may allow businesses to have more regulatory flexibility. For example, changes made inside a specified method operable design region (MODR) can be handled more efficiently without requiring regulatory reapproval as long as quality is maintained.

Compliance with ICH Q12: ICH Q14 improves upon ICH Q12 (Lifecycle Management), especially in relation to post-approval adjustments. When the analytical process is developed using Q14 principles, the ensuing control strategy and knowledge management system can more successfully enable effective management change over time.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Eberle M, Wasylenko JT, Kostelac D, Kiehna S, Schellinger A, Zhang Z, Ehrick JD. A modern framework for analytical procedure development and lifecycle management based on ICH Q14 principles. Analytical Chemistry. 2024 Dec 20;97(1):12-21.

2. Bhavyasri K, Vishnumurthy KM, Rambabu D, Sumakanth M. ICH guidelines–"Q" series (quality guidelines)-A review. GSC Biol Pharm Sci. 2019;6(3):089-106.

3. Bhavyasri K, Sreshta M, Sumakanth M. Scholars Academic Journal of Pharmacy.

4. Bhavyasri K, Dhanalakshmi C, Sumakanth M. Development and validation of ultra violet-visible spectrophotometric method for estimation of rivaroxaban in spiked human plasma. Journal of Pharmaceutical sciences and research. 2020 Sep 1;12(9):1215-9.

5. Tricht EV, Sänger-van de Griend CE. A practical approach to implementing ICH Q14: tools for analytical quality by design in capillary electrophoresis method development. Electrophoresis. 2025 Jul;46(13-14):933-53.

6. Guideline IH. Analytical procedure development Q14. International council for Harmonisation of technical requirements for pharmaceuticals for human use: Geneva, Switzerland. 2022 Mar 24.

7. Borman P, Hamilton P, Dierick JF. ICHQ14 Analytical Procedure Development. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. 2025 Apr 7:217-35.

8. Bhavyasri K, Sowjanya D, Begum S, Aishwarya B, Sumakanth M. UV-Method for the quantitative determination of sitagliptin in bulk and pharmaceutical dosage form and its validation including stability studies.

9. Bhavyasri K, Mounika C, Sumakanth M. Method Development, Validation and Forced Degradation Studies for Determination of Tigecycline in Bulk and Pharmaceutical Dosage Form using UV Spectroscopy. Journal of Young Pharmacists. 2020 Apr 2;12.

10. Bhavyasri K, Sowjanya D, Begum S, Aishwarya B, Sumakanth M. UV-Method for the quantitative determination of sitagliptin in bulk and pharmaceutical dosage form and its validation including stability studies.

11. Koteswaramma B, Dhiman S, Bhadrayya K, Jana A, Peraman R. AQbD-based headspace GC-MS/MS method development under ICH Q14 guidelines for simultaneous analysis of residual solvents in pharmaceuticals. Analyst. 2025;150(24):5481-500.

12. Sathuluri K, Bakam R, Jain R, Dande A, Gajbhiye R, Ravichandiran V, Peraman R. Analytical quality by design (AQbD) in the ICHQ14 guidelines for analytical procedure development. Accreditation and Quality Assurance. 2025 Feb;30(1):1-4.

13. Ojha A, Bhargava S. International council for harmonisation (ICH) guidelines. InRegulatory affairs in the pharmaceutical industry 2022 Jan 1 (pp. 47-74). Academic Press.

14. Conti M. ICH Q2 (R2) & Q14 Guidelines and impact on validation in OMCL Laboratories.

15. Salazar-Fontana LI, Drago D, RAC N. Can ICH Q14 Ease Regulatory Risks Around Impurity And Potency Testing?.

16. Furlanetto S, Orlandini S, Pieraccini G, Gotti R, Marzullo L, Pasquini B, Guiraldelli A. New trends in Quality Control: new compendial and ICH guidelines outlining Quality by Design (QbD) principles. InPBA 2023-33rd International Symposium on Pharmaceutical and Biomedical Analysis-Abstracts & Proceedings 2023 (pp. 35-35). PBA 2023-33rd International Symposium on Pharmaceutical and Biomedical Analysis.

17. Devdikar S, Shetkar B, Satpute K, Lohiya G, Sonvane S, Kore S, Kulkarni Y, Syed SM. Implementation of QbD approach in RP-HPLC method optimization and validation for concurrent estimation of Deflazacort and

18. Tamsulosin hydrochloride under ICH Q14 and Q2R2 framework. Current Pharmaceutical Analysis. 2025 Sep 16.

19. Hammond JP. Four generations of quality: a new approach. Spectroscopy Europe. 2022 Jan.

20. Panda SS, Bera RK, Sahu B. APPLICATION OF ICH Q14 CONCEPT FOR CHEMOMETRICS-ASSISTED DEVELOPMENT OF SPECTROPHOTOMETRIC METHODS FOR ESTIMATING PIMAVANSERIN IN TABLETS. Indian Drugs. 2022 Sep 1;59(9).

21. Gameiro BM. *Lifecycle management of process analytical methods for pharmaceuticals quality control* (Master's thesis, Universidade de Lisboa (Portugal)).

22. Verch T, Campa C, Chery CC, Frenkel R, Graul T, Jaya N, Nakhle B, Springall J, Starkey J, Wypych J, Ranheim T. Analytical Quality by Design, Life Cycle Management, and Method Control: Analytical Quality by Design, Life Cycle Management, and Method Control. The AAPS journal. 2022 Jan;24(1):34.

23. Harrington B. Analytical Target Profile. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. 2025 Apr 7:69-78.

24. Gaggero A, Jeremic D, Sattler R, Paudel A, Afonso Urich JA. Evaluation of Analytical Quality by Design Approaches on the Development and Optimization of Size Exclusion Chromatography Analytical Procedures for Bovine Serum Albumin. Journal of Separation Science. 2025 May;48(5):e70168.

25. Jain JK, Sujatha K, Sheelarani T, Trivedi H, Khemchandani R, Gananadhamu S. Analytical Quality by Design Enabled Green RP-HPLC Method Development and Validation for the Simultaneous Quantitation of the Cleaning Residues of Osimertinib, Binimetinib, and Erdafitinib: An Approach to Prevent the Cross Contamination in Shared Facilities of Pharmaceutical Manufacturing. Separation Science Plus. 2025 Sep;8(9):e70102.

26. Riley CM, Nguyen KL, editors. Specification of drug substances and products: development and validation of analytical methods. Elsevier; 2024 Sep 22.

27.Susmitha A, Rajitha G, Eri GK. A comprehensive review on QbD driven analytical procedures developed for the analysis of various drugs. Journal of Liquid Chromatography & Related Technologies. 2023 Mar 16;46(1-5):12-36.

28. Rani L, Mishra AK, SL N, Dewangan HK, Sahoo PK. An estimation of baricitinib by AQbD-driven UV spectrophotometry development and validation process. Letters in Drug Design & Discovery. 2024 Nov;21(14):2958-66.

29.Zompa MA, Merai D, Oram P, Lavrich DJ, Christopher JD, Quiroz J, Montefusco N, Newman A, Corcoran L, Zheng J, Zhang X. Application of Analytical Measurement Uncertainty and Considerations toward Pharmaceutical Material Quality Control Strategies. Analytical Chemistry. 2025 Dec 29.

30. JADHAV S. ICH Q14 Inspired-Qbd Mediated Development and Validation of Innovative Stability-Indicating HPLC Method For Estimating Melatonin From Sleep-Enhancing Tablet Formulation. AFRICAN JOURNAL OF BIOMEDICAL RESEARCH. 2024:6755-65.

31.Carter LH, Zhang E, O'connor N. Analytical Method Development in Pharmaceutical Sciences: A Comprehensive Review of Contemporary Frameworks, Lifecycle Approaches, and Regulatory Considerations.

32. Bonifas AP, Li Y. A practical approach to estimate analytical method variability from routine testing. Journal of Pharmaceutical and Biomedical Analysis. 2024 Oct 15;249:116344.

33. Mahr AG, Lourenço FR, Borman P, Weitzel J, Roussel JM. Analytical Quality by Design Fundamentals and Compendial and Regulatory Perspectives. InIntroduction to Quality by Design in Pharmaceutical Manufacturing and Analytical Development 2023 Jul 14 (pp. 163-198). Cham: Springer International Publishing.

34. Rish AJ, Henson S, Drennen JK, Anderson CA. Defining the range of calibration burden: from full calibration to calibration-free. Journal of Pharmaceutical Innovation. 2024 Jun;19(3):39.

35.Passerine BF, Breitkreitz MC. Important aspects of the design of experiments and data treatment in the analytical quality by design framework for chromatographic method development. Molecules. 2024 Dec 23;29(24):6057.

36. Simões A, Veiga F, Vitorino C. Question-based review for pharmaceutical development: An enhanced quality approach. European Journal of Pharmaceutics and Biopharmaceutics. 2024 Feb 1;195:114174.

37. Hanna-Brown M, Ermer J, Katzenbach S, Rignall A, Gervais A, Hoffmann J, Wypych J, McLaughlin K, Borman P, Grosche O. Analytical procedure lifecycle management: current status and opportunities. Pharm. Technol. 2018 Dec 2;42:18-23.

38. Sharma T, Jain A, Saini S, Katare OP, Singh B. Implementation of analytical quality-by-design and green analytical chemistry approaches for the development of robust and ecofriendly UHPLC analytical method for quantification of chrysin. Separation Science Plus. 2020 Sep;3(9):384-98.

39. Bairagi A, Kothrukar R, Chikhale H, Kosanam S, Borse L. AQbD-novel strategy for analytical methods. Future Journal of Pharmaceutical Sciences. 2024 Oct 4;10(1):138.

40. Pazhayattil A, Sharma S, Galande A, Rhoades R. Assessing manufacturing process robustness. BioPharm International. 2021 Jul 15;34(7):26-33.

41. Napa M, K VR, Ratnakaram VN, Dhuri S, Ramachandra B. Development and Validation of Quality by Design-Based HPLC Method for Impurity Profiling of Alprazolam. Separation Science Plus. 2025 Oct;8(10):e70147.

42. Tandel FB, Khandai M, Shah P, Panda DS, Patel VP. Analytical quality by design. InIntroduction to Quality by Design (QbD) From Theory to Practice 2024 Apr 10 (pp. 91-118). Singapore: Springer Nature Singapore.

43. Prajapati PB, Radadiya K, Shah SA. Quality risk management based: analytical quality by design approach to eco-friendly and versatile chromatography method for simultaneous estimation of multiple fixed-dose-combination products of anti-diabetic drugs. Journal of Pharmaceutical Innovation. 2022 Mar;17(1):111-28.

44. Chaursiya AC, Dumpala RL. A review on revision of ICH Q2 (R1) and new ICH Q14 guidance. Glo J Pharm All Sci. 2020;1(6):1-6.

45. Ortiz MC, Sarabia LA, Sánchez MS. The inversion of multiresponse partial least squares models, a useful tool to improve analytical methods in the framework of analytical quality by design. Analytica Chimica Acta. 2023 Oct 2;1276:341620.

46. Prajapati P, Tamboli J, Surati P, Mishra A. Risk assessment-based enhanced analytical quality-by-design approach to eco-friendly and economical multicomponent spectrophotometric methods for simultaneous estimation of montelukast sodium and bilastine. Journal of AOAC International. 2021 Sep 1;104(5):1453-63.

47. Borman P, Chatfield M, Asahara H, Tamura F, Watkins A. Risk-based intermediate precision studies for analytical procedure validation. Pharm. Technol. Regul. Sourceb. 2019;2019:12-22.

48. Sacré PY, De Bleye C, Beckers P, Hubert P, Ziemons EM. Development and Validation of Handheld Vibrational Spectroscopy Methods for the Quantitation of Active Ingredients in Pharmaceutical Solid Dosage Forms. Practical Quantitative Vibrational and Electronic Spectroscopy: A Guide for Developing, Optimizing, and Validating Procedures. 2025 Nov 26:289-306.

49. Mehrotra S, Kumar L. Implementation of quality by design in the formulation and development of nanocarrier-based drug delivery systems. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2023;40(3).

50. Roussel JM, Righezza M. Application of prediction intervals to the interpretation of analytical methods robustness studies. Journal of Pharmaceutical and Biomedical Analysis. 2021 Jan 30;193:113706.

51. BSA A. ADVANCING ANALYTICAL EXCELLENCE: A COMPREHENSIVE EXPLORATION OF ICH Q14 IN THE LIFECYCLE OF ANALYTICAL PROCEDURE DEVELOPMENT AND OPTIMIZATION. INTERNATIONAL RESEARCH JOURNAL ON ADVANCED ENGINEERING AND MANAGEMENT (IRJAEM) Учредители: RSP Science Hub. 2024;2(10):3090-8.

52. Breitkreitz MC. Analytical quality by design. Braz. J. Anal. Chem. 2021;8(32):1-5.

53. Delamotte N. Analytical lifecycle management within etherna.

54. Garshakunta S, Khan SA, Khan NA, Afreen N, Inshera HF, Qureshi MS. Advancements in Analytical Method Development and Validation: A Review of Current Trends and Challenges. Frontier Journal of Pharmaceutical Sciences and Research. 2025 Aug 10;8(2):6-12.

55. Acharya G, Pincus M, Gressard H, Borman P. Digitalization of QbD risk assessments. Pharmaceutical Technology. 2024 Mar:26.

56. Klick S. Specifications and analytical procedures in registration applications. InSpecification of Drug Substances and Products 2025 Jan 1 (pp. 221-257). Elsevier.

57. Nethercote P, Ermer J. Analytical validation within the pharmaceutical lifecycle. Method validation in pharmaceutical analysis: a guide to best practice. 2025 Apr 7:1-1.

58. Chaursiya AC, Dumpala RL. Global Journal for Pharma and Allied Sciences.

59. Chiarentin L, Gonçalves C, Augusto C, Miranda M, Cardoso C, Vitorino C. Drilling into "Quality by Design" approach for analytical methods. Critical Reviews in Analytical Chemistry. 2024 Nov 16;54(8):3478-519.

60. Maegawa H, Moore K. Enhancing Value of Global Pharmacopoeia Standards: Summary of Joint USP-MHLW/PMDA Workshop. BPB Reports. 2025;8(2):50-63.

61. Gellermann G, Mary Beth P, Wang Q, Winfield C, Castle B, Graul T, Cauchon N. Readiness for Implementation of ICH Q2 (R2) and Q14: Results of a Cross-Industry Survey. ISPE Pharmaceutical. 2025.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com